233 related articles for article (PubMed ID: 10364610)
1. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
Silvanose CD; Bailey TA; Di Somma A
Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
[TBL] [Abstract][Full Text] [Related]
8. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
9. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
[TBL] [Abstract][Full Text] [Related]
10. MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.
Salas V; Pastor FJ; Sutton DA; Calvo E; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1532-4. PubMed ID: 23295929
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
13. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.
Meletiadis J; Antachopoulos C; Stergiopoulou T; Pournaras S; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3329-37. PubMed ID: 17576838
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A; Mouton JW; Verweij PE; Tsakris A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Oct; 57(10):4656-63. PubMed ID: 23856768
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus.
Lass-Flörl C; Rief A; Leitner S; Speth C; Würzner R; Dierich MP
Antimicrob Agents Chemother; 2005 Jun; 49(6):2539-40. PubMed ID: 15917567
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].
García-Martos P; García-Agudo L; Gutiérrez-Calzada J; Ruiz-Aragón J; Saldarreaga A; Marín P
Enferm Infecc Microbiol Clin; 2005 Jan; 23(1):15-8. PubMed ID: 15701327
[TBL] [Abstract][Full Text] [Related]
19. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
20. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
Al-Wathiqi F; Ahmad S; Khan Z
BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
